These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 17706036)

  • 1. [Efficacy of low-dose heparin and prostaglandin E1 in the prevention of hepatic veno-occlusive disease after allogenic hematopoietic stem cell transplantation in children with beta-thalassemia major].
    Sun X; Hao WG; Liu S; Xia T; Liao C
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Aug; 9(4):343-6. PubMed ID: 17706036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention of hepatic veno-occlusive disease by a combination of heparin and prostaglandin E1 in children undergoing hematopoietic stem cell transplantation].
    Inukai T; Sugita K; Goi K; Akahane K; Hirose K; Nemoto A; Takahashi K; Sato H; Uno K; Furuichi Y; Nakamura M; Miyamoto N; Yamakawa N; Shiraishi K; Kojika S; Tezuka T; Iijima K; Nakazawa S
    Rinsho Ketsueki; 2004 Apr; 45(4):297-303. PubMed ID: 15168445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prophylaxis of hepatic veno-occlusive disease by low-molecular-weight heparin and lipo- prostaglandin E1 after allogeneic peripheral blood stem cell transplantation].
    Song CY; Li YH; Guo KY; Wu BY
    Di Yi Jun Yi Da Xue Xue Bao; 2003 May; 23(5):494, 497. PubMed ID: 12754143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Low dose heparin for the prevention of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation].
    Chen J; Zhu KE; Zhang T; Zhong J; Chen ST; Zeng HL
    Zhonghua Nei Ke Za Zhi; 2007 Feb; 46(2):140-2. PubMed ID: 17445443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preventive effect of integrated Chinese and Western medicine on hepatic veno-occlusive disease after hematopoietic stem cell transplantation].
    Liu J; Zhang X; Chen XH
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Oct; 30(10):1049-51. PubMed ID: 21066888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficiency of prevention and treatment of veno-occlusive disease of the liver after allogeneic stem cell transplantation].
    Dong M; Lin Q; Wu XY
    Ai Zheng; 2008 Jun; 27(6):646-9. PubMed ID: 18570742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A trial use of prostaglandin E1 for prevention of hepatic veno-occlusive disease after allogeneic bone marrow transplantation].
    Morio S; Oh H; Kogure K; Ishii H; Ishii A; Nakaseko C; Ikegami T; Kawano E; Matsuura Y; Nishimura M
    Rinsho Ketsueki; 1994 Sep; 35(9):846-52. PubMed ID: 7967053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.
    Song JS; Seo JJ; Moon HN; Ghim T; Im HJ
    J Korean Med Sci; 2006 Oct; 21(5):897-903. PubMed ID: 17043426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A clinical analysis of hepatic veno-occlusive disease after hematopoietic stem cell transplantation].
    Qin CJ; Liu LJ; Zhang ZM; Luo L; Lai YR; Li QC
    Zhonghua Nei Ke Za Zhi; 2018 Jul; 57(7):483-486. PubMed ID: 29996265
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
    Kallianpur AR; Hall LD; Yadav M; Byrne DW; Speroff T; Dittus RS; Haines JL; Christman BW; Summar ML
    Bone Marrow Transplant; 2005 Jun; 35(12):1155-64. PubMed ID: 15834437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
    Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
    Cacchione A; LeMaitre A; Couanet DV; Benhamou E; Amoroso L; Simonnard N; Hartmann O
    Bone Marrow Transplant; 2008 Oct; 42(7):449-54. PubMed ID: 18587430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
    Park SH; Lee MH; Lee H; Kim HS; Kim K; Kim WS; Jung CW; Im YH; Yoon SS; Kang WK; Park K; Park CH; Kim SW
    Bone Marrow Transplant; 2002 Jan; 29(2):137-43. PubMed ID: 11850708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
    Tefferi A; Kumar S; Wolf RC; Lacy MQ; Inwards DJ; Gloor JM; Albright RC; Kamath PS; Litzow MR
    Bone Marrow Transplant; 2001 Nov; 28(10):997-9. PubMed ID: 11753559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.
    Méresse V; Hartmann O; Vassal G; Benhamou E; Valteau-Couanet D; Brugieres L; Lemerle J
    Bone Marrow Transplant; 1992 Aug; 10(2):135-41. PubMed ID: 1525602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Allogeneic peripheral blood stem cell transplantation for 3 patients with beta-thalassemia major and 1 patient with congenital idiopathic haemolytic anemia].
    Fang J; Huang S; Chen C; Wu Y; Bao R; Huang K
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2001 Dec; 18(6):452-5. PubMed ID: 11774214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation.
    Iguchi A; Kobayashi R; Yoshida M; Kobayashi K; Matsuo K; Kitajima I; Maruyama I
    Bone Marrow Transplant; 2001 Jun; 27(11):1173-80. PubMed ID: 11551028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.
    Bouligand J; Le Maitre A; Valteau-Couanet D; Grill J; Drouard-Troalen L; Paci A; Hartmann O; Benhamou E; Vassal G
    Clin Pharmacol Ther; 2007 Oct; 82(4):402-9. PubMed ID: 17392724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.